Immunohistochemistry detection of DNA mismatch repair in colorectal cancer

Presented by

Dr. Weiqi Sheng, Fudan University Shanghai Cancer Center & Dr. Ying Kong, Roche Diagnostics Solutions

About this talk

This webinar, sponsored by Roche, aims to provide an understanding of the scientific development and significance of DNA mismatch repair (MMR) deficiency testing in colorectal cancer (CRC), including MMR mechanism, the clinical impact of dMMR/MSI determination in CRC, testing methodology and case discussion. Dr. Sheng will share perspectives derived from clinical cases and experiences related to MMR testing. Dr. Sheng is a professor and the chief pathologist at Fudan University Shanghai Cancer Center. Dr. Sheng is one of China's leading experts in gastrointestinal cancer and malignant lymphoma with 20 years of pathology experience. A member of multiple national professional committees and a key author on diagnostic guidelines, Dr. Sheng has published over 120 research papers and has been actively involved in multiple clinical trials.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (61)
Subscribers (7659)
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.